sources:
  - id: mdgl_10k_2024
    category: sec_filing
    description: Madrigal Form 10-K for FY 2024
    agency_or_origin: SEC
    url: "https://www.sec.gov/Archives/edgar/data/1157601/000162828024007376/0001628280-24-007376-index.htm"
    local_path: sec/mdgl_10k_2024.html
    notes: Annual filing with audited financials, rNPV context, and pipeline disclosures.
  - id: mdgl_10q_recent
    category: sec_filing
    description: Most recent Madrigal Form 10-Q (Q3 2025)
    agency_or_origin: SEC
    url: "https://www.sec.gov/Archives/edgar/data/1157601/000162828025048559/0001628280-25-048559-index.htm"
    local_path: sec/mdgl_10q_2025_q3.html
    notes: Provides updated launch KPIs, cash runway, and guidance.
  - id: mdgl_key_8k
    category: sec_filing
    description: Key 8-K covering results of operations (Feb 26 2025)
    agency_or_origin: SEC
    url: "https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/0001193125-25-035787-index.htm"
    local_path: sec/mdgl_8k_rezdiffra_update.html
    notes: Use for rapid reference when major clinical or commercial events are disclosed.
  - id: rezdiffra_us_label
    category: regulatory_label
    description: Rezdiffra US Prescribing Information (FDA label)
    agency_or_origin: FDA
    url: "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf"
    local_path: regulatory/rezdiffra_us_label.pdf
    notes: Core label with indications, dosing, warnings; cite in report/notes.
  - id: rezdiffra_fda_review
    category: regulatory_review
    description: FDA multi-discipline review / approval package (NDA 217785)
    agency_or_origin: FDA
    url: "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217785Orig1s000TOC.cfm"
    local_path: regulatory/rezdiffra_fda_review.html
    notes: Contains efficacy/safety review, statistical memos, and labeling negotiation history.
  - id: rezdiffra_ema_epar
    category: regulatory_review
    description: EMA EPAR for Rezdiffra
    agency_or_origin: EMA
    url: "https://www.ema.europa.eu/en/medicines/human/EPAR/rezdiffra"
    local_path: regulatory/rezdiffra_ema_epar.html
    notes: Tracks EU benefit-risk assessment once published; good for comparator insights.
  - id: maestro_nash_publication
    category: clinical_trial
    description: MAESTRO NASH pivotal trial publication (NEJM 2024)
    agency_or_origin: New England Journal of Medicine
    url: "https://r.jina.ai/https://www.nejm.org/doi/full/10.1056/NEJMoa2309000"
    local_path: clinical/maestro_nash_publication.html
    notes: Cite for efficacy/safety tables and subgroup analyses; proxied through r.jina.ai for easier downloading.
  - id: ctgov_maestro_nash
    category: clinical_trial
    description: ClinicalTrials.gov entry for MAESTRO NASH (NCT03900429)
    agency_or_origin: ClinicalTrials.gov
    url: "https://clinicaltrials.gov/study/NCT03900429"
    local_path: clinical/ctgov_maestro_nash.html
    notes: Source for official design, endpoints, and status updates.
  - id: ctgov_maestro_nafld1
    category: clinical_trial
    description: ClinicalTrials.gov entry for MAESTRO NAFLD-1 (NCT04197479)
    agency_or_origin: ClinicalTrials.gov
    url: "https://clinicaltrials.gov/study/NCT04197479"
    local_path: clinical/ctgov_maestro_nafld1.html
    notes: Documents safety/biomarker study that informs launch assumptions.
  - id: ctgov_maestro_nash_outcomes
    category: clinical_trial
    description: ClinicalTrials.gov entry for MAESTRO NASH Outcomes (NCT05500222)
    agency_or_origin: ClinicalTrials.gov
    url: "https://clinicaltrials.gov/study/NCT05500222"
    local_path: clinical/ctgov_maestro_nash_outcomes.html
    notes: Track event-driven outcomes readout timing for catalyst calendar.
  - id: mdgl_investor_presentation_h1
    category: corporate_presentation
    description: Madrigal investor presentation – Q1 2025 results deck
    agency_or_origin: Company IR
    url: "https://ir.madrigalpharma.com/static-files/5e3a8be1-ad1d-49d6-a679-25163ac071d4"
    local_path: corporate/mdgl_investor_presentation_q1_2025.pdf
    notes: Contains launch dashboards and reimbursement talking points.
  - id: mdgl_investor_presentation_h2
    category: corporate_presentation
    description: Madrigal investor presentation – Q2 2025 results deck
    agency_or_origin: Company IR
    url: "https://ir.madrigalpharma.com/static-files/de6afb62-d8f7-4c81-ab36-25714e924681"
    local_path: corporate/mdgl_investor_presentation_q2_2025.pdf
    notes: Updated KPIs plus scenario commentary; useful for model calibration.
  - id: mdgl_earnings_call_q2_2024
    category: press_release
    description: Q2 2024 earnings call transcript
    agency_or_origin: Seeking Alpha
    url: "https://r.jina.ai/https://seekingalpha.com/article/4711556-madrigal-pharmaceuticals-inc-mdgl-q2-2024-earnings-call-transcript"
    local_path: earnings/mdgl_q2_2024_transcript.html
    notes: Transcript of August 7 2024 call; proxied copy to avoid paywall blocks.
  - id: mdgl_earnings_call_q3_2024
    category: press_release
    description: Q3 2024 earnings call transcript
    agency_or_origin: Seeking Alpha
    url: "https://r.jina.ai/https://seekingalpha.com/article/4731686-madrigal-pharmaceuticals-inc-mdgl-q3-2024-earnings-call-transcript"
    local_path: earnings/mdgl_q3_2024_transcript.html
    notes: Transcript of October 31 2024 call; proxied copy for easy download.
